Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Cerevel Therapeutics to Present Results from a Phase 2 Study of Tavapadon in Patients with Early-stage Parkinson's Disease


Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present new data from a Phase 2 clinical trial evaluating tavapadon (formerly PF-06649751) in patients with early-stage Parkinson's disease at the 2019 International Congress of Parkinson's Disease and Movement Disorders®, taking place from September 22-26 in Nice, France. Tavapadon is a novel, investigational, orally-administered, selective partial agonist of the dopamine D1 and D5 receptors.

Details of the poster presentation are as follows:

Title: Efficacy, Safety and Tolerability of Tavapadon in Subjects with Early Stage Parkinson's Disease
Abstract Number: 98
Authors: David L. Gray, Robert Riesenberg, John Werth, Yao Zhang, Mark Versavel, Sridhar Duvvuri
Session Title: Clinical Trials, Pharmacology and Treatment
Date/Time: Monday, September 23, 2019 from 1:45 to 3:15 p.m. CEST (7:45 to 9:15 a.m. EDT)
Location: Nice Acropolis Convention Centre, 1 Esplanade Kennedy 06364, Nice Cedex 4, France

About Cerevel Therapeutics
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is unlocking new treatment opportunities by understanding the neurocircuitry of the symptoms. Cerevel Therapeutics has a diversified pipeline comprising four clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson's, epilepsy, schizophrenia and addiction. Headquartered in Boston, Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit www.cerevel.com.


These press releases may also interest you

at 20:25
AHF Praises Colombia for Putting Lives Before Pharma Greed
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC Deputy Registrar, Kathy Lauriente, honoured with Distinguished Service Award from Thompson Rivers University (TRU)
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT Expands to Meet the Growing Need for Self-Harm, Suicidal Thoughts, and Depression Therapy.
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
Notice - NOVA TECH LTD and CYNTHIA PETION, File No. 2023-20
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated Announces Increased First Quarter Dividend
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...

More news about Health...


News published on and distributed by: